AFFiRiS AG

Profile

  • RDM* biotech/pharma
  • Founded in: 2003
  • Staff: 61
  • Indications: G00 - G99 I60 - I99 E00 - E90
  • Topic: Human health
  • Cluster Membership: LISAvienna
  • Profile: AFFiRiS develops first-in-class specific active immunotherapies (SAIT) for the prevention and treatment of chronic illnesses. SAIT candidates are based on a flexible modular system consisting of peptides conjugated to carrier proteins and an adjuvant. Our proprietary AFFITOME®-Technology delivers peptides that are close variants of a target specific epitope and are optimized for immunogenicity, thereby inducing an antibody response that is cross-reactive to the original target.
  • R&D: Our clinical stage projects focus on Atherosclerosis prevention targeting PCSK9 and Parkinson’s disease targeting α synuclein. Our pre-clinical projects focus on Huntington's targeting mutHTT and other undisclosed targets.

Contact